Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Leases German Biologics Manufacturing Facility from Bayer

publication date: Jan 16, 2020

WuXi Biologics signed a long-term lease for a German biologics manufacturing plant owned by Bayer AG. WuXi will also purchase the facility's equipment from Bayer and provide back-up manufacturing for its Kovaltry™, a recombinant treatment for Hemophilia Factor A. In 2018, WuXi Biologics released plans to spend $800 million to build four biologics manufacturing facilities around the globe, including a $395 million facility in Ireland that was expected to be the company's first European manufacturing site. More details....

Stock Symbols: (HK: 2269) (Xetra: BAYN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.